Companies: 10,795·Total market cap: $144.5T

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

NTLANASDAQHealthcare● Active

$13.47

$-0.07(-0.52%)

Market Cap$1.5B

P/E Ratio—

52W High$28.25

52W Low$7.31

Avg Volume5.4M

Open$13.83

Beta1.81

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Intellia Therapeutics, Inc.（NTLA）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · NTLA · 截至 Jun 8, 2026

关键指标

EPS (TTM)$-3.54Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)$66.1MFull revenue history

Dividend Yield不分红Dividend history

Shares Outstanding108.4MShares outstanding history

Next EarningsAug 6, 2026Est.Earnings history

探索 Intellia Therapeutics, Inc. 数据

分析师预测$26 · Buy

股息不分红

营收$67.7M+16.92%

盈利EPS $-3.81+27.43%

财务快照

FY 2025Revenue$67.7M▲ +16.92% YoY

202320242025

FY 2025Net Income-$412.7M▲ +20.49% YoY

202320242025

FY 2025EPS$-3.81▲ +27.43% YoY

202320242025

TTM:Revenue: $66.1MNet Income: -$394.6MEPS: $-3.54View income statement →

分析师评级与目标价

Buy39 位分析师

Strong Buy

0

Buy

28

Hold

9

Sell

2

Strong Sell

0

12-Month Price Target

$13.00Low

$13.47Current

$26.29Avg Target上涨空间 95.17%

$49.00High

合计: 39 · 买入占比: 71.8%

根据过去 3 个月内 39 位华尔街分析师，NTLA 共识评级为 Buy，12 个月平均目标价 $26.29 （较现价 $13.47 上涨空间 95.17%）。

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Intellia Therapeutics, Inc.

$13.47-0.52%$1.5B #2

BioCryst Pharmaceuticals, Inc.

$8.33-0.74%$1.7B #3

$11.16+3.10%$1.2B #4

$18.47+0.05%$1.8B #5

$31.50+1.45%$2.2B #6

Stoke Therapeutics, Inc.

$29.14-2.92%$1.8B

股票表现

1D-8.20%

1W+4.39%

1M-3.90%

3M+0.74%

YTD+50.61%

1Y+63.53%

5Y-82.86%

关于 Intellia Therapeutics, Inc.

CEOJohn Leonard

IPO DateMay 6, 2016

Employees403

CountryUS

Websiteintelliatx.com

Intellia Therapeutics, Inc. a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatmen…

Biotechnology HealthcareNASDAQUS

关于股票概览与关键数据

Intellia Therapeutics, Inc.（NTLA）是 Biotechnology 行业的 Healthcare 类公司，于 May 6, 2016 在 NASDAQ 上市。截至最近交易日，NTLA 股价为 $13.47，市值约为 $1.5B。过去12个月累计回报 +63.53%，年初至今回报 +50.61%。

根据 39 位华尔街分析师，Intellia Therapeutics, Inc. 股票共识评级为Buy，12个月平均目标价为 $26.29。2025 财年 Intellia Therapeutics, Inc. 营收 $67.7M，净利润 -$412.7M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，Intellia Therapeutics, Inc.（NTLA）股价为 $13.47，在 NASDAQ 上市，52周区间为 $7.31 – $28.25。

NTLA 最新股价NTLA quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 8, 2026本内容不构成投资建议